CMS is rolling out a GLP-1 “Bridge” program under Medicare to expand access to obesity drugs, but the design has raised immediate questions about cost, supply, and implementation. The pilot seeks to manage coverage transitions while maintaining patient access to medications in the GLP-1 class. Industry stakeholders and policy observers are weighing whether the program’s operational details can keep pace with demand, particularly given known supply constraints that can affect continuity of treatment. The pilot’s performance will likely be measured by plan reach, administration capacity, and downstream clinical use. For biopharma, the news highlights a near-term reimbursement lever that could alter prescribing dynamics for anti-obesity medications while testing payer systems’ ability to administer coverage at scale.